Background: Preclinical and clinical evidence suggest that the neuropeptide oxytocin may be of value in treating alcohol use disorder, by either reducing the rewarding effects of alcohol or reducing negative affect induced by alcohol withdrawal. However, the effect of a single dose of oxytocin on subjective and psychomotor responses to alcohol in social drinkers is not known.
D ESPITE ADVANCES IN treatments for alcoho use disorders (AUD)
, there remains an urgent need for novel approaches to reduce problematic drinking. One promising new candidate as a medication for AUD and other substance use disorders is the neuropeptide oxytocin. Preclinical studies suggest that oxytocin may reduce the reinforcing properties and other behavioral effects of alcohol (Bahi, 2015; Bowen et al., 2015; Peters et al., 2017) . In humans, there is early evidence that oxytocin dampens desire for marijuana, nicotine, and for alcohol in current and detoxified alcoholics (McRae-Clark et al., 2013; Miller et al., 2016; Pedersen, 2017; Sherman et al., 2017) . Yet, no studies have examined effects of oxytocin on responses to acute alcohol administration in nondependent, social drinkers. Therefore, the current pilot study sought to assess the effects of intranasal oxytocin on subjective, behavioral, and physiological responses to a moderate dose of alcohol in healthy social drinkers.
Oxytocin is an endogenous peptide hormone that is synthesized in the paraventricular and supraoptic nuclei of the hypothalamus Viero et al., 2010) . It is released centrally via dendritic and terminal mechanisms, and peripherally via the posterior pituitary (Lee and Weerts, 2016) . G protein-coupled oxytocin receptors are widely distributed throughout the central nervous system, including in regions implicated in reinforcement and reward processing (Viero et al., 2010) . In addition to its well-known role in sexual and maternal behaviors, oxytocin appears to facilitate pro-social behaviors, including increased empathy, trust, and the tendency to favor members of an in-group (Bethlehem et al., 2013; Mitchell et al., 2015; Viero et al., 2010) . There is also both preclinical and clinical evidence that oxytocin attenuates anxiety and responses to stress (Bethlehem et al., 2013; Heinrichs et al., 2003; Lee and Weerts, 2016; Mitchell et al., 2015; Viero et al., 2010) , effects that may indirectly reduce alcohol craving and consumption in problem users (Fox et al., 2007; Magrys and Olmstead, 2015) . Evidence also suggests that oxytocin has an inhibitory effect on learning and memory (Sarnyai and Kov acs, 2014; de Wied et al., 1993) , and this may hold relevance for substance use disorders, in which maladaptive learning and memory processes are a central feature.
Oxytocin also interacts with the mesolimbic dopamine system, which may influence subjective responses to alcohol. For example, in rats, oxytocin injected into the ventral tegmental area increases extracellular dopamine in the nucleus accumbens, and this effect is blocked by oxytocin receptor antagonists (Melis et al., 2007) . Activation of the mesolimbic dopamine system contributes to alcohol's reinforcing effects and may have a role in alcohol's subjective effects in humans (Aalto et al., 2015; Boileau et al., 2003; Hendler et al., 2011; Samson et al., 1992; Urban et al., 2010; Yoder et al., 2005) . Possibly via its interactions with dopaminergic systems, exogenous oxytocin administration appears to reduce the reinforcing effects of alcohol in rodent models (Bahi, 2015; Burkett and Young, 2012; King et al., 2017; MacFadyen et al., 2016; Peters et al., 2017; Stevenson et al., 2017) . Because reinforcing effects are closely linked with positive subjective effects in humans, it is reasonable to speculate that oxytocin may also reduce subjective alcohol responses in humans.
Interestingly, oxytocin may also decrease the sedative and motor-impairing effects of moderate doses of alcohol, but whether these effects translate to humans is unclear. In a recent study with rats, a 1.5 g/kg dose of ethanol (EtOH) produced significant motor impairments on wire-hanging and righting-reflex tests, as well as reduced locomotor activity in an open-field test (Bowen et al., 2015) . Rats pretreated with oxytocin showed an attenuation of EtOH-induced impairment at 5 and 35 minutes postalcohol administration. Oxytocin, however, did not reduce the motor-impairing effects of a 3 g/kg dose of alcohol. To date, no clinical studies have assessed oxytocin's effects on alcohol-induced impairments in psychomotor performance.
There are few reports of interactions between oxytocin and alcohol in humans. One small pilot study examined effects of oxytocin (24 IU twice a day for 3 days) in 7 alcohol-dependent patients undergoing acute inpatient withdrawal. Relative to placebo (n = 4), oxytocin decreased the amount of lorazepam needed to treat withdrawal symptoms during acute detoxification (Pedersen et al., 2013) . In a randomized clinical trial, 22 heavy drinkers self-administered daily doses of oxytocin (40 IU, 2 to 3 times daily) or placebo for 12 weeks. Compared to placebo, oxytocin significantly reduced the number of drinks per drinking day and marginally reduced the number of heavy drinking days, but had no effect on craving or anxiety scores (Pedersen, 2017) . The authors suggest that these findings indicate a reversal of alcohol tolerance. These 2 reports suggest that oxytocin reduces both withdrawal symptoms and alcohol consumption.
This study was designed to determine whether intranasal oxytocin reduces responses to a single, moderate dose of alcohol in healthy volunteers. Based on the evidence described above, we hypothesized that oxytocin would reduce the positive subjective responses to alcohol. Furthermore, because oxytocin reduced EtOH-induced sedation and motor impairment in rats (Bowen et al., 2015) , we also hypothesized that intranasal oxytocin would dampen alcohol-induced psychomotor and neurocognitive impairment, relative to placebo. We assessed the effects of oxytocin during both the ascending and descending limbs of the blood alcohol curve to monitor its time course of effect and determine its effects over a range of blood alcohol concentrations (Fillmore and Weafer, 2012; Fillmore et al., 2005; Schweizer and Vogel-Sprott, 2008) .
MATERIALS AND METHODS

Overall Design
The study used a mixed within-and between-subject design to examine the effect of oxytocin versus placebo on subjective and behavioral responses to an alcohol or placebo challenge. During 2 study sessions, healthy social drinkers received nasal sprays containing placebo on one session and oxytocin on the other session, in random order. Sprays were administered both shortly before consuming a beverage and again after the beverage. Half of the participants received alcohol at both sessions (ALC), and half received placebo beverages at both sessions (NoALC; between-subjects). Dependent measures included self-report ratings of subjective effects of both the nasal sprays and the beverages, as well as computerbased cognitive and psychomotor behavioral tasks, blood pressure, and heart rate. The Institutional Review Board of the University of Chicago approved the study, and it was carried out in accordance with the Declaration of Helsinki.
Participants
Thirty-five healthy social drinkers (19 male, 16 female) were recruited via community flyers and online advertisements. Screening included a psychiatric evaluation and a physical examination. Inclusion criteria were age 21 to 35 years, at least a high school education, body mass index (BMI) between 19 and 26, and English fluency. Further, only candidates consuming at least 6 drinks per week with at least 1 binge episode (per the NIAAA guidelines of 4 drinks for women and 5 drinks for men; "NIAAA drinking levels defined," https://www.niaaa.nih.gov/alcohol-health/overview-alc ohol-consumption/moderate-binge-drinking) in the past 30 days were included, based on a retrospective Timeline Follow Back (TLFB; Sobell and Sobell, 1992) calendar. Candidates were excluded if they had a current DSM-5 major psychiatric disorder (American Psychiatric Association, 2013), history of alcohol or other substance dependence (except nicotine), performed night shift work, were taking regular medications (except birth control), or had a history of nasal surgery, hyponatremia, diabetes insipidus, or syndrome of inappropriate antidiuretic hormone. Women who were pregnant, nursing, or planning to become pregnant were excluded from participation.
Participants provided written informed consent prior to enrollment into the study. They were told that they would receive nasal sprays containing either a hormone, such as vasopressin or oxytocin, or placebo, and beverages containing alcohol or placebo at each session. Participants were instructed to consume their normal amounts of caffeine and nicotine in the days leading up to the sessions, but to abstain from food, nicotine, and caffeine for 2 hours prior to each session. They were also instructed to refrain from alcohol and other recreational drugs for at least 24 hours prior to each study session. Women using hormonal contraceptives were tested at any time in their menstrual cycle, but those not using contraceptives (n = 3) were tested only in the follicular phase to control for fluctuations in endogenous hormone levels (Miller et al., 2016; Weafer et al., 2016) .
Procedures
Sessions took place at the Human Behavioral Pharmacology Laboratory at the University of Chicago. Participants first completed an orientation session, during which they practiced the cognitive and psychomotor behavioral tasks and were familiarized with the study protocol and questionnaires. The sessions were conducted with participants individually situated in a comfortable living-room-like space with couches, a computer (for data collection and task administration only), and a selection of magazines, as well as movies available to participants when measures were not being obtained.
The 2 study sessions took place from 12 to 6 PM, Monday through Saturday, and were separated by at least 7 days. The session timeline is summarized in Fig. 1 . Upon arrival, participants provided breath (measured via AlcoSensor IV Breathalyzer; Intoximeters, Inc., St. Louis, MO) and urine (measured via Rapid Drug Test; CLIAwaived Inc., San Diego, CA) samples to detect recent alcohol and drug use, and pregnancy in women (measured via CLIAwaived Inc.). Sessions were rescheduled if participants tested positive for alcohol or drugs (except THC; 3 participants in ALC and 5 in NoALC tested positive for THC prior to both sessions). After breath and urine tests, participants completed baseline subjective questionnaires (prebeverage Biphasic Alcohol Effects Scale [BAES] , Drug Effects Questionnaire [DEQ] , and Subjective Effects of Alcohol Scales [SEAS] ) and underwent heart rate and blood pressure readings (measured via Omron Blood Pressure Monitor; Omron Healthcare, Lake Forest, IL) followed by a light snack (Nature Valley Crunchy Granola Bars; General Mills, Minneapolis, MN). Then, they received nasal sprays containing either oxytocin (40 IU) or placebo (see Drugs below). Fifteen minutes after the sprays, they completed visual analog questionnaires assessing response to oxytocin. Then, they consumed a beverage in 3 small portions (ALC (0.8 g/kg for males, 0.68 g/kg for females) or NoALC; see Drugs below). A research assistant was present and conversed with the participants during beverage consumption. Twenty minutes after finishing the beverage, participants completed the first round of cognitive and psychomotor behavioral tasks (see below), corresponding with the ascending limb of the blood alcohol curve. Then, they received a second nasal spray with the same contents as the first (the oxytocin dose for the second, booster spray was 20 IU), and repeated the cognitive and psychomotor tasks, corresponding with the descending limb of the blood alcohol curve. Other dependent measures included breath alcohol concentration (BrAC) and vital sign measurements, mood, and subjective drug effects questionnaires every 15 to 60 minutes throughout the session until 6 PM When BrAC was below 0.04% (usually by 6 PM), the experimental session ended.
To assess the blind, each study session ended with a survey asking the participants which drug (oxytocin, vasopressin, or placebo) they believed that they received in the nasal sprays and beverages (alcohol or placebo), as well as to rate whether they felt any effects of the spray and beverages ("I felt no effect," "I think I felt a mild effect, but am not sure," "I definitely felt an effect, but it was not strong," "I felt a strong effect," "I felt a very strong effect"). Following oxytocin sessions, while 57% of participants reported feeling a mild effect of the sprays, only 26% of participants indicated that they believed that they had receive oxytocin. Following the placebo session, 51% of participants reported feeling a mild effect of the sprays and 34% of participants correctly labeled the placebo. All participants who received alcohol correctly indicated that the beverages contained alcohol, while those who received placebo correctly indicated that the beverages did not contain alcohol 70% of the time.
Behavioral Tasks. Four neurocognitive and psychomotor tasks were used to assess specific cognitive processes that are impaired by acute alcohol: digit span, flanker task, go/no-go task, and pursuit rotor (Fillmore, 2003; Fillmore et al., 2005; Grattan-Miscio and Vogel-Sprott, 2005; Mann and Vogel-Sprott, 1981; Maylor and Rabbitt, 1993; Schweizer et al., 2006) . The tasks were obtained from the Psychology Experiment Building Language (PEBL; Mueller and Piper, 2014) , and subjects completed the tasks in random order, 20 and 70 minutes after consuming their beverages. The tasks took 20 minutes to complete. Due to technical errors, 3 participants' data from the NoALC group were lost or incomplete.
Digit Span-The digit span task is a working memory task that consists of visual presentation of a series of numbers, one at a time. After the series of numbers is displayed, the participant must respond by typing the numbers in the same in order in which they appeared. The number of digits displayed is increased by 1 digit every 2 trials, up to a maximum of 10. The task ends when the participant incorrectly responds on 2 consecutive trials or after 10 digits. The primary outcome measures are memory span (the maximum number of digits correctly recalled) and the number of total correct trials.
Flanker Task-The flanker task in PEBL is a modified version of the Eriksen flanker task (Eriksen and Schultz, 1979) , which assesses conditional accuracy and reaction time with distractors. Participants respond by indicating the direction toward which a central arrow is pointing. On some trials, the central arrow is flanked by congruent arrows (pointing in the same direction) and on other trials by incongruent arrows (pointing in the opposite direction), dashes, or nothing. The primary outcome measures are accuracy, mean response time, and number of errors.
Measures/Tasks:
Behavioral tasks X X Oxytocin-specific subjective VAS X X BrAC X X X X X X X X BAES, SEAS, DEQ X X X X X X X Heart rate, blood pressure X X X X X X X X 12:00 p.m.
6:00 p.m. 1:00 2:00 3:00 4:00 5:00
Drink Period Nasal Spray Nasal Spray Go/No-Go Task-The go/no-go task in PEBL assesses response inhibition and reaction time (Bezdjian et al., 2009 ). The task requires participants to attend to the presentation of letters and respond to the target letter (go signal), while suppressing responses to the distractor letter (no-go signal). The screen shows a 2 9 2 array, with each quadrant containing a star. On each trial, one of the stars is randomly replaced with a letter P or R, with P's appearing in greater frequency. In the first condition, participants are instructed to respond to the presentation of the letter P in any of the 4 quadrants and suppress responses to the letter R. In the reversal condition, participants are instructed to respond to the presentation of the letter R and suppress responses to the letter P. The primary outcome measures are the total number of errors (commission and omission) and the mean response time under each condition.
Pursuit Rotor-The pursuit rotor task assesses motor dexterity by requiring the participant to use a computer mouse to follow a target moving along a circular track (Piper et al., 2015) . The target moves at a fixed rate, and participants perform four 15-second trials. The total time on the target is the primary outcome measurement.
Subjective Effects. Subjective effects of oxytocin were assessed with visual analog scales on which subjects rated themselves on the following items: tense, dreamy, focused, excited, dizzy, anxious, relaxed, alert, calm, friendly, withdrawn, social, content, drowsy, stimulated, and tired on a scale of 0 to 100. Subjective effects of alcohol (or placebo beverage) were assessed via the DEQ (Fischman and Foltin, 1991; Morean et al., 2013a,b) assessing overall magnitude of drug effect, drug liking and disliking, and wanting, as well as the BAES (Martin et al., 1993) and the Subjective Effects of Alcohol Scale (SEAS; Morean et al., 2013a) .
Drugs
Alcohol and oxytocin were administered under double-blind conditions. Alcohol beverages (ALC) were prepared with 95% alcohol (Everclear; Luxco Inc., St. Louis, MO) and orange juice. The volume of 500 to 900 ml (depending on the participant's body weight) was evenly distributed into 3 plastic cups administered at 5-minute intervals. The dose was chosen to produce peak blood alcohol concentrations of 0.08 mg% (0.80 g/kg for males, 0.68 g/kg for females; based on body weight). In the placebo beverage condition (NoALC), subjects received an equivalent volume of orange juice distributed evenly among 3 cups, each with a 1 ml "floater" of 95% alcohol.
Intranasal oxytocin (OT) doses were prepared within 24 hours of administration by the University of Chicago Hospital investigational pharmacy. A single dose of Pitocin (OT Injection USB; Monarch Pharmaceuticals, Bristol, TN; concentration: 10 IU Pitocin/ 1 ml) was distributed into syringes (1 ml/syringe). Placebo (PL) nasal sprays consisted of Ocean Spray Nasal Solution (Valeant Pharmaceuticals, Bridgewater, NJ), placed in 1-mL syringes. Atomizers (MAD300; LMA Inc., San Diego, CA) were affixed to the syringes to facilitate administration. The nasal sprays were administered over a 5-minute period by trained personnel. The nasal sprays contained 0.5 ml per inhalation. During the first administration before the beverage, they received 8 inhalations (40 IU total; 2 ml/nostril) and then at the booster dose after the beverage they received a further 4 inhalations (20 IU; 1 ml/nostril).
Data Analysis
BrACs were analyzed using repeated-measures ANOVA with the within-subjects factors of time and spray (OT vs. PL).
Subjective responses to the first dose of oxytocin were analyzed via a 2-way ANOVA with time (pre-and postnasal sprays) and spray (PL and OT) as the within-subject factors, collapsed across ALC and NoALC. Post hoc t-tests were used to follow up on any significant interactions. Because subjective responses to oxytocin may be modulated by gender (Olff et al., 2013) , secondary ANOVAs included gender as a covariate.
Subjective, behavioral, and physiological responses were separately analyzed via 3-way repeated-measures ANOVAs, each with the within-subjects factors of time and spray (OT vs. PL), and between-subjects factor of beverage (ALC vs. NoALC). Simple effects post hoc tests were conducted on any interactions that were statistically significant (p < 0.05) to identify alcohol or OT effects. In separate repeated-measures ANOVAs conducted only on the data from the ALC group, average number of drinks per week, as determined from TLFB, was included as a covariate to determine whether the effects of oxytocin on alcohol response were related to recent drinking history (King et al., 2011) . Table 1 summarizes the demographic characteristics for the alcohol (ALC) and placebo (NoALC) groups. The groups did not differ in age, BMI, number of years of education, or current drug and alcohol use. Overall, participants reported consuming about 12 AE 1.1 alcohol drinks per week and 4.2 AE 0.6 binge episodes during the past month.
RESULTS
Demographics
Subjective Effects of the Initial Dose (40 IU) of Oxytocin
Based on self-report questionnaires completed immediately before and 15 minutes after the first nasal spray (i.e., before consuming any beverage), oxytocin did not produce any changes in subjective effects relative to placebo. Secondary analyses exploring the role of gender on the 18.6 (9.0); n = 7 10.4 (9.2); n = 10 0.09
Alcohol use (past month) # Drinks/wk 11.7 (7.3) 12.4 (5.7) 0.77 # Binges/month 4.1 (3.2) 4.4 (3.5) 0.76 a n = number of participants endorsing past month use; means were calculated using only participants who reported any use. subjective effects of intranasal oxytocin indicated that compared to women, men exhibited a marginally significant increase in ratings of "alert" after oxytocin ( Fig. 2 ; spray 9 time 9 gender repeated-measures ANOVA, F(1, 31) = 3.48, p = 0.07. No other sex differences were observed.
Breath Alcohol Concentrations
BrACs are shown in Fig. 3 . Participants attained a mean peak BrAC of 0.084 AE 0.003 mg/l at approximately 40 minutes following beverage consumption. Men attained a higher peak BrAC than women (peak BrAC males = 0.087 AE 0.005 mg/l, peak BrAC females = 0.081 AE 0.003 mg/l; time 9 gender interaction: F(7, 126) = 4.33, p < 0.001). Oxytocin did not alter BrAC.
Subjective Alcohol Responses
Relative to the placebo beverage, alcohol produced its expected subjective effects (Fig. 4) , but oxytocin did not change these effects. Alcohol significantly increased BAES stimulation scores at 15 minutes following beverage consumption (time 9 beverage interaction: F(6, 198) = 3.59, p = 0.002) and increased BAES sedation scores throughout the session (time 9 beverage interaction: F(6, 198) = 2.81, p = 0.012). It also increased DEQ ratings on all scales, except "dislike drug" throughout the session (time 9 beverage interactions: "feel drug," F(6, 198) = 18.46, p < 0.001; "want more," F(6, 198) = 6.47, p < 0.001; "like drug," F(6, 198) = 9.46, p < 0.001; "feel high," F(6, 198) = 17.17, p < 0.001; Fig. 4) . On the SEAS, alcohol increased both high positive arousal (time 9 beverage interaction: F(6, 198) = 4.68, p < 0.001; spray 9 time 9 beverage interaction: F(6, 198) = 2.10, p = 0.055; Fig. 4 ) and low negative arousal (F(6, 198) = 4.23, p < 0.001). Participants in the NoALC condition did not report increases on any of these measures. Subjective responses to alcohol did not differ based on recent drinking history. Oxytocin had no effect on any of the subjective effects.
Behavioral Tasks
Alcohol impaired performance on the digit span and go/ no-go tasks, but oxytocin had no effect on these measures. Relative to the NoALC group, subjects in the ALC group remembered fewer digits (mean AE SEM: ALC, 7.4 AE 0.2; NoALC, 8.4 AE 0.2, F(1, 29) = 5.28, p = 0.029) and completed fewer correct trials (mean AE SEM: ALC, 9.8 AE 0.3; NoALC, 11.5 AE 0.4, F(1, 29) = 4.37, p = 0.045). In the go/ no-go task, alcohol marginally increased response times during the reversal condition (mean AE SEM: ALC, 546.3 AE 6.8 ms; NoALC, 502.1 AE 9.9 ms, F(1, 28) = 3.99, p = 0.056). Oxytocin did not affect performance on any task or alter the effects of alcohol on the digit span and go/no-go tasks, and recent drinking history was not related to performance measures.
Physiological Effects
Relative to placebo, alcohol produced modest cardiovascular effects but oxytocin did not alter on these responses. Alcohol decreased both systolic (SBP) and diastolic (DBP) blood pressure (time 9 drink interaction for: SBP, F(7, 231) = 3.75, p < 0.001; DBP, F(7, 231) = 3.72, p < 0.001). The effects on SBP occurred at 90 and 270 minutes postbeverage consumption. While there were no significant differences in DBP between ALC and NoALC at specific time points, alcohol significantly decreased DBP relative to baseline, F(1, 33) = 14.84, p < 0.001, at 65 to 270 minutes postbeverage consumption (p < 0.05). Alcohol increased heart rate (time 9 drink interaction: F(7, 231) = 3.93, p < 0.001), 15 minutes and 150 to 270 minutes following beverage consumption. Oxytocin did not alter the physiological effects of alcohol.
DISCUSSION
This study examined the effects of intranasal oxytocin on behavioral, subjective, and physiological responses to alcohol in social drinkers. Alcohol (0.8 g/kg for males, 0.68 g/kg Fig. 4 . Ratings of subjective alcohol effects. The y-axis indicates the mean rating values (AE SEM) for each item. Time = 0 minutes represents the completion of beverage consumption, and nasal sprays occurred at Time = À30 and 40 minutes. *Indicates statistical significance for ALC versus NoALC (p < 0.01); **Indicates significant time 9 beverage interaction (p < 0.001).
for females) produced its expected subjective effects, impaired performance on psychomotor tasks and produced expected cardiovascular effects. However, oxytocin did not modulate any of these effects. Therefore, the results do not support the hypothesis that oxytocin attenuates responses to alcohol in this population of neurotypical, young adult, social drinkers.
Our findings do not fit simply with evidence from rodents suggesting that oxytocin reduced the reinforcing or the motor-impairing effects of alcohol (Bahi, 2015; Bowen et al., 2015; King et al., 2017; MacFadyen et al., 2016; Peters et al., 2017; Stevenson et al., 2017) . Reinforcing effects in rodents are often linked to positive subjective responses in humans. In rats, oxytocin also reduces the sedation and motor impairment induced by alcohol in a wire-hanging test and loss of righting-reflex test (Bowen et al., 2015) . In the present study, oxytocin did not reduce subjective ratings of "liking" alcohol, the positive, stimulating effects of alcohol, or alcohol-induced sedation and impairments on either a go/no-go task or digit span task. There are many possible reasons why our findings in humans do not correspond with the rodent studies. First, the doses and routes of administration of alcohol and oxytocin used in the rodent versus human studies may not be comparable, and the pharmacokinetics of the drugs may differ. For example, in the Bowen and colleagues (2015) study, oxytocin was administered directly into the central nervous system via the cerebral ventricles, whereas in the present study, oxytocin was administered intranasally. Therefore, we are unable to make comparisons regarding the dose of peptide reaching targets in the brain. Second, there may be cross-species differences in how oxytocin affects behavior and there are clear differences in the measures used to assess alcohol "reward" in rodents versus humans, or motor impairment (e.g., wire-hanging vs. reaction time). The difficulty in designing truly translational studies in human and nonhuman species remains a significant challenge to the field (Stephens et al., 2011) .
Several previous studies in alcohol-dependent individuals suggested that oxytocin might have therapeutic potential for alcohol use (Mitchell et al., 2016; Pedersen, 2017; Pedersen et al., 2013) . Pedersen (2017) and Pedersen and colleagues (2013) reported that oxytocin reduced both alcohol withdrawal severity and anxiety in detoxifying AUD patients, and reduced the number of drinks per drinking day among heavy drinkers meeting DSM-IV criteria for alcohol dependence. Mitchell and colleagues (2016) reported that oxytocin reduced cue-induced craving for alcohol in AUD patients with high scores on relationship anxiety. These previous clinical findings are consistent with the idea that oxytocin has anxiolytic effects, which might be most apparent during withdrawal or in anxious individuals. It has also been proposed that oxytocin may reduce or inhibit tolerance induced by chronic, long-term alcohol use Pedersen, 2017; Szab o et al., 1985 Szab o et al., , 1989 Tirelli et al., 1992) . It was difficult to address these ideas in this study, in which the participants were young adult social drinkers without significant anxiety, and without evidence of either acute or chronic tolerance (Brumback et al., 2007; Fillmore and Weafer, 2012) on psychomotor performance. The design of this study did not allow us to evaluate oxytocin's effects on acute or chronic tolerance to alcohol. It is possible that the effects of oxytocin might be evident only in individuals who are alcohol-dependent and/or report some moderate levels of negative affect, anxiety, or depression.
More broadly, the present study supports prior findings that the subjective and behavioral effects of intranasal oxytocin in humans are inconsistent and variable based on contextual and individual factors. In the present study, participants correctly indicated which drug they had received in the nasal spray only about 30% of the time. Similarly, in a recent meta-analysis of 38 clinical studies involving exogenous oxytocin administration, 93% of participants were unable to distinguish between oxytocin and placebo, and the hormone produced subtle and inconsistent behavioral effects (MacDonald et al., 2011) . There are several possible reasons why it has been difficult to detect a robust effect of oxytocin. First, the effects may be subtle and not readily apparent using standard behavioral tasks. Further, the effects of oxytocin may depend on context (Bartz et al., 2011; Bethlehem et al., 2014) or individual factors, such as gender, attachment style, polymorphisms in the oxytocin receptor gene, and endogenous oxytocin levels (Bartz et al., 2011; Bethlehem et al., 2014; Feng et al., 2015; Olff et al., 2013; Sumracki et al., 2014) . While our exploration of gender differences in self-reported subjective effects of oxytocin yielded no significant findings, our analyses may have been limited by the small sample size. It remains to be determined under what conditions this neuropeptide produces its behavioral effects.
Further complicating our interpretation of the present findings is the lack of empirical data on the pharmacokinetic profile of intranasal oxytocin in humans. Several small studies in nonhuman primates quantified the effect of intranasal oxytocin on central concentrations of the peptide, primarily via assaying the cerebrospinal fluid (CSF). While some show increased CSF concentrations of oxytocin within 30 to 60 minutes of intranasal administration (Chang et al., 2012; Dal Monte et al., 2014; Freeman et al., 2016; Modi et al., 2014) , another shows no significant changes (Modi et al., 2014) . A recent study demonstrated the penetrance of exogenous oxytocin into the central nervous system in rhesus macaques using isotope-labeled intranasal oxytocin (80 IU) (Lee et al., 2017) . However, the pharmacokinetics of intranasal oxytocin are likely to be different in humans. Indeed, there is evidence that absorption of oxytocin can be enhanced simply by communicating to the participant to inhale during nasal administration (Guastella et al., 2013; Modi et al., 2014; Striepens et al., 2013) , as was carried out in the current study. Although it is difficult to measure brain levels of peptides in humans, 1 study reported modest increases in CSF oxytocin in 4 participants 75 minutes following intranasal administration (Striepens et al., 2013) . Nevertheless, the concentration reaching receptor targets in the brain is unknown, as is a complete understanding of oxytocin's dose-response effects.
The present study had several limitations. First, we tested only a single dose of oxytocin. This dose (40 IU with 20 IU booster 75 minutes later) was based on published work (Churchland and Winkielman, 2012; Feifel et al., 2010; MacDonald et al., 2011 MacDonald et al., , 2013 , and the known short half-life of oxytocin (Arias, 2000; Churchland and Winkielman, 2012; Gossen et al., 2012) . A complete determination of the effects of oxytocin should include a full dose-response function. Second, the tasks selected to detect alcohol-induced impairment were not highly sensitive and significant effects on performance were observed on only 2 of the 4 tasks. More sensitive measures might be needed to detect subtle effects of oxytocin on psychomotor and neurocognitive performance. Further, we did not assess performance before the sprays on each session, and so we could not rule out prespray baseline differences in the alcohol versus placebo groups. However, as we did not observe any effect of the spray, this is a minor concern. Third, the number of subjects was relatively small. None of our results suggest that we would detect effects in a larger sample. However, it is possible that effects may be observed in more demographically heterogeneous subjects, including those with heavier drinking histories or a higher level of anxiety or negative mood states.
The present study contributes to a growing body of literature on how oxytocin may affect drug and alcohol use. There is some evidence that oxytocin reduces craving for drugs among drug users under conditions of stress or anxiety (McRae-Clark et al., 2013; Mitchell et al., 2016; Pedersen et al., 2013) , but not among users in nonstressed conditions (Lee et al., 2014; Woolley et al., 2016) . The present findings indicate that the hormone has little effect in nondependent social drinkers who are tested under stress-free conditions. Collectively, these findings are consistent with the hypothesis that the effects of exogenous oxytocin are dependent on contextual and individual factors, which must be considered when designing future studies. Further, oxytocinergic pathways may be altered by chronic drug and alcohol use; thus, the effects of intranasal oxytocin are less evident in social or moderate users.
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